EphA3受体截短突变体variant b在前列腺癌细胞中的分泌表达

目的:验证EphA3受体截短突变体variant b是否是一种分泌蛋白,并探索其内源分泌的特点,在细胞水平看其是否有作为前列腺癌血清标志物的潜质。方法:构建EphA3 variant b真核表达载体,应用标签抗体、特异性抗体和Western印迹检测前列腺癌细胞培养液中EphA3 variant b的表达,用RT-PCR方法分析EphA3 variant b在8种细胞系中的表达谱和对雄激素刺激的应答。结果:验证了EphA3 variant b是一种分泌蛋白,在雄激素受体阳性的前列腺癌细胞系中特异性表达,雄激素以剂量依赖方式诱导EphA3 variant b表达。结论:EphA3 variant b是一种分泌蛋白,其表达与雄激素受体信号通路相关,有作为前列腺癌血清标志物的潜质。     

一个新的前列腺癌细胞系分泌蛋白磷酸甘油酸酯激酶的鉴定与分析

目的：建立前列腺癌细胞系C4-2B分泌蛋白双向电泳图谱,并对感兴趣的蛋白进行质谱鉴定,对其表达调控进行初步分析。方法：收集前列腺癌细胞系C4-2B的分泌蛋白,利用双向电泳结合质谱的方法对感兴趣的蛋白进行鉴定,而后利用Western blot等方法对结果进行验证和分析。结果：得到较为稳定的前列腺癌细胞系分泌蛋白C4-2B双向电泳图谱,鉴定了一个新的前列腺癌细胞系分泌蛋白磷酸甘油酸酯激酶,并发现1nmol/L人工合成雄激素R1881可上调其表达。结论：建立了简便的前列腺癌细胞系分泌蛋白双向电泳及质谱分析的研究方法,初步证明磷酸甘油酸酯激酶是前列腺癌细胞系C4-2B新的分泌蛋白,且人工合成雄激素R1881可诱导其表达上调。     

PC-1在前列腺癌细胞中促进c-myc基因的表达

前列腺癌相关基因PC-1(Prostate and colon gene1)是属于癌基因D52家族成员,具有促进前列腺癌细胞雄激素非依赖性生长的功能。为了研究PC-1发挥这种生物功能的分子机制,文章在PC-1高表达的LNCaP-pc-1及对照LNCaP-zero细胞中,利用RT-PCR和Western blotting等方法检测c-myc基因表达;提取两细胞胞质和胞核蛋白,利用Western blotting分析c-myc上游调节蛋白β-catenin变化;利用c-Myc蛋白抑制剂10058-F4作用前列腺癌细胞C4-2,Western blotting检测PC-1蛋白表达变化。发现PC-1促进c-myc基因表达,并促进β-catenin入核;c-Myc蛋白抑制剂10058-F4可抑制PC-1的表达。结果表明:PC-1在前列腺癌中促进c-myc基因的表达,并且这种促进作用可能是通过Wnt/β-catenin信号通路实现的。同时,PC-1与c-Myc蛋白间可相互促进,进一步促进前列腺癌细胞雄激素非依赖性生长。     

不同病理睾丸组织中雄激素受体和热休克蛋白90α表达的差异

目的检查和分析不同病理睾丸组织雄激素受体和热休克蛋白90α表达的差异.方法运用免疫组织化学二步法检查精子发生停滞、精原细胞瘤、前列腺癌去势和正常健康睾丸标本之雄激素受体和热休克蛋白90α的表达情况.结果正常睾丸组织和前列腺癌去势睾丸中雄激素受体在间质细胞、支持细胞和精原细胞的胞核表达,前者的表达强度高于后者(P<0.05);热休克蛋白90α主要在类肌细胞、间质细胞、支持细胞核及生精细胞的胞浆表达.精子发生阻滞的睾丸组织,雄激素受体主要在支持细胞的胞核和生精细胞的胞浆表达,热休克蛋白90α主要在支持细胞、类肌细胞表达;精原细胞瘤的睾丸组织,雄激素受体在肿瘤细胞的胞浆和胞核表达,热休克蛋白90α的表达强度在精原细胞瘤组织高于对照标本.结论雄激素受体核转运异常与精子发生阻滞有紧密关系;前列腺癌去势患者睾丸组织中,雄激素受体免疫反应强度减弱与睾丸衰老有关;精原细胞瘤患者睾丸标本,雄激素受体表达减弱,但热休克蛋白90α表达增强;提示雄激素受体和热休克蛋白90α的表达异常与精原细胞瘤的病理发生有关.     

巴氏杆菌糖酵解酶的黏附作用研究

巴氏杆菌（主要是多杀性巴氏杆菌）可以引起多种动物疫病（巴氏杆菌病）,同时也引起人类感染发病。[目的] 研究巴氏杆菌糖酵解酶对宿主细胞（兔肾细胞）和两种常见分子[纤连蛋白（fibronectin,Fn）和血浆纤维蛋白溶解酶原（plasminogen,Plg）]的黏附作用。[方法] 采用原核表达系统对多杀性巴氏杆菌的糖酵解酶进行表达并纯化及制备多克隆抗体,通过菌体表面蛋白定位检测、黏附与黏附抑制等实验探究巴氏杆菌糖酵解酶的黏附作用。[结果] 菌体表面蛋白检测结果显示除烯醇化酶和丙酮酸激酶外的7个糖酵解酶在多杀性巴氏杆菌表面存在。这7个糖酵解酶均能黏附兔肾细胞,但仅有磷酸葡萄糖异构酶的多克隆抗体能对多杀性巴氏杆菌黏附宿主细胞产生抑制作用。Far Western blotting结果显示9个糖酵解酶均能结合宿主Fn和Plg。招募抑制实验结果显示磷酸葡萄糖异构酶、醛缩酶、磷酸甘油酸变位酶的抗体对多杀性巴氏杆菌结合Fn和Plg都有抑制作用,磷酸果糖激酶、丙糖磷酸异构酶、甘油醛-3-磷酸脱氢酶、磷酸甘油激酶抗体仅对多杀性巴氏杆菌结合Fn或Plg有抑制作用。[结论] 多杀性巴氏杆菌糖酵解酶成员葡萄糖异构酶、磷酸果糖激酶、醛缩酶、丙糖磷酸异构酶、甘油醛-3-磷酸脱氢酶、磷酸甘油激酶、磷酸甘油酸变位酶在多杀性巴氏杆菌黏附宿主细胞或分子过程中发挥作用。该研究的完成将加深巴氏杆菌病分子发病机制的认识,并为巴氏杆菌病的诊断标识筛选、新型疫苗创制和药物靶标筛选等提供基础数据。     

日本血吸虫中国大陆株TPI基因的克隆及其表达产物特性

磷酸丙糖异构酶（ＴＰＩ）是血吸虫病疫苗重要的候选抗原基因之一。参考日本血吸虫已发表的ＴＰＩｃＤＮＡ序列,以日本血吸虫中国大陆株成虫ｍＲＮＡ为模板,用ＲＴ－ＰＣＲ法快速克隆出一大小约８００ｂｐ的ＤＮＡ片段。ＤＮＡ序列分析证实,所扩增到的ＤＮＡ片段即为日本血吸虫中国大陆株磷酸丙糖异构酶（ＳｊＴＰＩｃ）基因。将该基因重组到表达型质粒ｐＧＥＸ－４Ｔ中,表达的ＧＳＴ融合蛋白分子量约５４ｋＤ。用谷胱甘肽琼脂糖凝胶亲和层析柱纯化的重组蛋白不仅纯度好,而且得率高,纯化产量可达３０ｍｇ／Ｌ培养物。免疫试验结果表明该重组蛋白具有良好的抗原性,是一种较为理想的抗原分子。     

日本血吸虫中国大陆株TPI基团的克隆及其表达产物特性

磷酸丙糖异构酶（ＴＰＩ）是血吸虫病疫苗重要的候选抗原基因之一。参考日本血吸虫已发表的ＴＰＩ ｃＤＮＡ序列,以日本血吸虫中国大陆株成虫ｍＲＮＡ为模板,用ＲＴ－ＰＣＲ法快速克隆出一大小约８００ｂｐ的ＤＮＡ片段。ＤＮＡ序列分析证实,所扩增到的ＤＮＡ片段即为日本血吸虫中国大陆株磷酸丙糖异构酶（ＳｊＴＰＩｃ）基因。将该基因重组到表达型质粒ｐＧＥＸ－４Ｔ中,表达的ＧＳＴ融合蛋白分子量约５４ｋＤ。用谷胱甘肽琼脂     

脊髓全横断损伤后差异表达蛋白的蛋白质组学分析

 对脊髓全横断损伤前后的大鼠脊髓全蛋白质进行双向凝胶电泳,借助PDQuest软件从中找出差异表达蛋白质点.应用基质辅助激光解吸电离串联质谱,对差异表达的蛋白质点进行鉴定,成功鉴定出18种蛋白质.脊髓损伤3 d后表达上调的蛋白质有巨噬细胞游走抑制因子、S期激酶相关蛋白 1、热休克蛋白 27、多配体蛋白聚糖 3、T细胞受体β链可变区、膜联蛋白Ⅲ、腺苷酸激酶 1、半乳凝素 3、丙酮酸脱氢酶、磷脂酶 B、嗜铬粒蛋白 A、热休克蛋白70凝结蛋白 1;同时表达下调的蛋白质有磷酸丙糖异构酶、神经鞘氨醇磷酸化受体、热休克蛋白10、肽酰 脯氨酰 顺反式异构酶 A多数差异蛋白质涉及到神经细胞的增殖、凋亡、应激反应等过程,为进一步阐明中枢神经系统的损伤和修复机制提供了理论依据.摘要 对脊髓全横断损伤前后的大鼠脊髓全蛋白质进行双向凝胶电泳,借助PDQuest软件从中找出差异表达蛋白质点.应用基质辅助激光解吸电离串联质谱,对差异表达的蛋白质点进行鉴定,成功鉴定出18种蛋白质.脊髓损伤3 d后表达上调的蛋白质有巨噬细胞游走抑制因子、S期激酶相关蛋白 1、热休克蛋白 27、多配体蛋白聚糖 3、T细胞受体β链可变区、膜联蛋白Ⅲ、腺苷酸激酶 1、半乳凝素 3、丙酮酸脱氢酶、磷脂酶 B、嗜铬粒蛋白 A、热休克蛋白70凝结蛋白 1;同时表达下调的蛋白质有磷酸丙糖异构酶、神经鞘氨醇磷酸化受体、热休克蛋白10、肽酰 脯氨酰 顺反式异构酶 A多数差异蛋白质涉及到神经细胞的增殖、凋亡、应激反应等过程,为进一步阐明中枢神经系统的损伤和修复机制提供了理论依据.     

MSX1通过与GRP78相互作用促进前列腺癌细胞PC-3增殖

同源异型框蛋白在发育中具有非常重要的作用,而同源异型框蛋白的异常表达和很多人类疾病相关,其中就包括前列腺癌的发生发展。我们通过分析TCGA数据库中前列腺癌病人样本MSX1的表达量发现,在肿瘤样本中MSX1表达量显著高于非肿瘤样本。因此我们检测正常永生化前列腺基底细胞系WPMY-1、雄激素依赖的前列腺癌细胞系LNCa P、雄激素非依赖的前列腺癌细胞系PC-3中MSX1的表达量,发现在雄激素依赖的前列腺癌细胞系LNCa P中MSX1表达量最高。为了探究MSX1在前列腺癌细胞中的作用,我们选取MSX1表达量较低且不受雄激素调控的PC-3细胞作为研究对象。研究表明过表达MSX1可以显著促进PC-3细胞的增殖。我们通过免疫沉淀技术确定了MSX1与GRP78蛋白相互作用,而GRP78蛋白可以调控AKT、ERK1/2等细胞周期相关蛋白从而调控细胞周期等细胞进程。因此推测MSX1通过和GRP78相互作用从而促进前列腺癌细胞增殖。我们的研究为阐明MSX1在前列腺癌发生发展中作用机理提供了一定的理论参考依据。     

14-3-3蛋白和神经退行性疾病

14-3-3蛋白以二聚体形式存在,识别磷酸丝氨酸／苏氨酸连接的信号分子,通过与其配体蛋白质相互作用,参与细胞信号转导、细胞周期调控和细胞问运输。14-3-3蛋自在脑组织中含量丰富,所有神经元、星形胶质细胞、少突肢质细胞、小胶质细胞的胞液与胞核中都有表述。14-3-3蛋白与神经退行性疾病阿尔茨海默病和帕金森病的发生过程关系密切。     

PC-１基因表达增强C4-2B前列腺癌细胞生存

建立稳定表达外源PC-１基因的人前列腺癌骨转移C4-2B细胞模型,初步探讨PC- １基因表达对前列腺癌发展的影响.通过脂质体介导的方法,将融合PC-１基因的真核表达载体pcDNA3.1PC-１稳定转染C4-2B细胞,Western 印迹和RT-PCR技术,分别从蛋白水平和RNA水平确定外源PC-１基因表达. MTT和软琼脂集落形成能力等一系列方法,研究PC-１基因的功能,RT-PCR和实时定量PCR检测前列腺癌发生发展相关基因表达的变化. 结果表明,PC-１基因的高表达能够诱导雄激素受体（AR）调控基因和一系列重要的信号通路成员基因PSA、PSMA、NKX31、Jagged1、EphA3、SGEF和 NOTCH3等表达发生变化. 实验结果初步证明,PC-１基因表达在晚期前列腺癌中,以及在雄激素非依赖的转变中可以发挥作用,PC-１基因表达可调控一些重要信号通路.对PC-１基因功能深入研究将有可能为发现新的前列腺癌的诊断治疗分子靶标提供线索.     

Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells

We investigated the effects of androgen receptor (AR) down regulation with a small interference RNA molecule (siRNA_AR(start)) on androgen sensitive LNCaP and androgen independent LNCaPabl prostate cancer cells, the latter representing an in vitro model for the development of therapy resistance in prostate cancer. Although LNCaPabl cells express increased levels of AR in comparison with androgen sensitive LNCaP cells, the protein was significantly down regulated in response to siRNA_AR(start) treatment. This AR down regulation resulted in a marked cell growth inhibition in both cell lines. By contrast, DU-145 prostate cancer cells, which lack AR expression, were not inhibited by the siRNA_AR(start). In consequence to AR down regulation, both cell lines, LNCaP and LNCaPabl, shared a highly similar gene expression profile in terms of major changes in cell cycle regulatory genes. The cell cycle inhibitor p21(Waf1/Cip1) as well as cyclin D1 were significantly up regulated by siRNA_AR(start) treatment, considering a switch in cyclin expression towards cell cycle retardation. Control molecules had moderate effects on cell proliferation and gene expression, respectively. In summary, we found that AR inhibition with siRNA induces cell growth retardation in androgen sensitive as well as in androgen independent prostate cancer cells and thus may represent an interesting approach to combat hormone-refractory prostate cancer.     

Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer

Metastasis represents the ultimate target in cancer therapy as this complex biological process is the direct cause of mortality for a variety of human malignancies. The current high level of mortality from prostate cancer results in large part from the inexorable growth of overt or occult metastasis present at the time of diagnosis. Currently, there are no curative therapies for metastatic prostate cancer. To better understand the metastatic phenotype in prostate cancer, we developed a strategy to identify mRNAs that are expressed differentially in cell lines derived from primary versus metastatic mouse prostate cancer using differential display-PCR. In using this system a number of metastasis-related sequences were identified including a cDNA that encodes caveolin-1. Caveolin-1 was found to be overexpressed not only in metastatic mouse prostate cancer, but also in human metastatic disease. Recent studies have indicated that suppression of caveolin-1 expression induces androgen sensitivity in high caveolin-1, androgen-insensitive mouse prostate cancer cells derived from metastases. Conversely, overexpression of caveolin-1 leads to androgen insensitivity in low caveolin, androgen-sensitive mouse prostate cancer cells. Caveolin-1, therefore, is both a metastasis-related gene as well as a candidate androgen resistance gene for prostate cancer in man. Interestingly, recent studies also point to a potential role for caveolin-1 in the resistance of various malignancies to multiple antineoplastic agents. The linkage of caveolin-1 expression with the androgen-resistant phenotype in prostate cancer and the multidrug resistance phenotype in various solid tumors establishes a novel paradigm for understanding these clinically important and now potentially related processes in malignant progression.     

与人PC-1同源的鼠PC-1基因的启动子的分子克隆和特性分析

为了鉴定鼠mPC-1基因表达的调控元件,克隆并分析了该基因的启动子.构建了一系列mPC-1基因启动子的截短序列.通过荧光素酶报道基因,分析了它们在前列腺癌细胞和其它细胞中的表达.结果表明,在AR阳性细胞系中,mPC-1基因启动子活性远远高于SV40和p61-PSA 启动子,mPC-1基因启动子 599 bp 至449bp 可能含有一个负调控元件; mPC-1 1.1 kb 启动子控制的表达主要在前列腺癌细胞系中; 雄激素可调控mPC-1 1.1kb 启动子表达.mPC-1 1.1kb 序列是一个有前列腺癌细胞特异性和较强的启动子,经过进一步的修饰有可能作为一种有用的前列腺癌基因治疗元件.     

Androgen Regulated Genes in Human Prostate Xenografts in Mice: Relation to BPH and Prostate Cancer

Benign prostatic hyperplasia (BPH) and prostate carcinoma (CaP) are linked to aging and the presence of androgens, suggesting that androgen regulated genes play a major role in these common diseases. Androgen regulation of prostate growth and development depends on the presence of intact epithelial-stromal interactions. Further, the prostatic stroma is implicated in BPH. This suggests that epithelial cell lines are inadequate to identify androgen regulated genes that could contribute to BPH and CaP and which could serve as potential clinical biomarkers. In this study, we used a human prostate xenograft model to define a profile of genes regulated in vivo by androgens, with an emphasis on identifying candidate biomarkers. Benign transition zone (TZ) human prostate tissue from radical prostatectomies was grafted to the sub-renal capsule site of intact or castrated male immunodeficient mice, followed by the removal or addition of androgens, respectively. Microarray analysis of RNA from these tissues was used to identify genes that were; 1) highly expressed in prostate, 2) had significant expression changes in response to androgens, and, 3) encode extracellular proteins. A total of 95 genes meeting these criteria were selected for analysis and validation of expression in patient prostate tissues using quantitative real-time PCR. Expression levels of these genes were measured in pooled RNAs from human prostate tissues with varying severity of BPH pathologic changes and CaP of varying Gleason score. A number of androgen regulated genes were identified. Additionally, a subset of these genes were over-expressed in RNA from clinical BPH tissues, and the levels of many were found to correlate with disease status. Our results demonstrate the feasibility, and some of the problems, of using a mouse xenograft model to characterize the androgen regulated expression profiles of intact human prostate tissues.     

Endoplasmic reticulum stress,autophagic and apoptotic cell death,and immune activation by a natural triterpenoid in human prostate cancer cells

Though the current therapies are effective at clearing an early stage prostate cancer, they often fail to treat late-stage metastatic disease. We aimed to investigate the molecular mechanisms underlying the anticancer effects of a natural triterpenoid, ganoderic acid DM (GA-DM), on two human prostate cancer cell lines: the androgen-independent prostate carcinoma (PC-3), and androgen-sensitive prostate adenocarcinoma (LNCaP). Cell viability assay showed that GA-DM was relatively more toxic to LNCaP cells than to PC-3 cells (IC₅₀s ranged 45-55 µM for PC-3, and 20-25 µM for LNCaP), which may have occurred due to differential expression of p53. Hoechst DNA staining confirmed detectable nuclear fragmentation in both cell lines irrespective of the p53 status. GA-DM treatment decreased Bcl-2 proteins while it upregulated apoptotic Bax and autophagic Beclin-1, Atg5, and LC-3 molecules, and caused an induction of both early and late events of apoptotic cell death. Biochemical analyses of GA-DM-treated prostate cancer cells demonstrated that caspase-3 cleavage was notable in GA-DM-treated PC-3 cells. Interestingly, GA-DM treatment altered cell cycle progression in the S phase with a significant growth arrest in the G2 checkpoint and enhanced CD4 ⁺ T cell recognition of prostate tumor cells. Mechanistic study of GA-DM-treated prostate cancer cells further demonstrated that calpain activation and endoplasmic reticulum stress contributed to cell death. These findings suggest that GA-DM is a candidate for future drug design for prostate cancer as it activates multiple pathways of cell death and immune recognition.     

Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2

We analyzed gene expression of MBD1, MBD2, MBD3, MBD4, and MeCP2 and protein expression of MBD1, MBD2, and MeCP2 in prostate cancer cell lines, benign prostate epithelium (BPH-1) cell line, 49 BPH tissues, and 46 prostate cancer tissues. The results of this study demonstrate that MBD2 gene is expressed in all samples and MeCP2 gene is expressed in all cancer cell lines but not in BPH-1 cell line. However, there was no protein expression for MBD2 and MeCP2 in cancer cell lines and cancer tissues. For CXXC sequence containing MBD1, both protein and mRNA were expressed in cancer cell lines, cancer tissues, BPH-1 cell line, and BPH tissues. We observed that, in BPH tissues and low-grade cancer tissues, MBD1 protein expression was very high and gradually decreased with increase of cancer grade. Treatment of cancer cell lines with proteasome inhibitor (MG-132) did not restore expression of MBD2 and MeCP2 proteins. When prostate cancer cell lines were treated with hypomethylating agent, 5-aza-2(')-deoxycytidine (DNMT inhibitor), HDAC1 and HDAC2 expression was decreased. This is the first report demonstrating that CXXC sequence containing MBD1 is overexpressed and can be the major factor of hypermethylated chromatin segments through HDAC1/2 translocation and histone deacetylation in human prostate cancer.     

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer

Deciphering molecular pathways involved in the early steps of prostate oncogenesis requires both in vitro and in vivo models derived from human primary tumors. However the few recognized models of human prostate epithelial cancer originate from metastases. To date, very few models are proposed from primary tumors and immortalizing normal human prostate cells does not recapitulate the natural history of the disease. By culturing human prostate primary tumor cells onto human epithelial extra-cellular matrix, we successfully selected a new prostate cancer cell line, IGR-CaP1, and clonally-derived subclones. IGR-CaP1 cells, that harbor a tetraploid karyotype, high telomerase activity and mutated TP53, rapidly induced subcutaneous xenografts in nude mice. Furthermore, IGR-CaP1 cell lines, all exhibiting negativity for the androgen receptor and PSA, express the specific prostate markers alpha-methylacyl-CoA racemase and a low level of the prostate-specific membrane antigen PSMA, along with the prostate basal epithelial markers CK5 and CK14. More importantly, these clones express high CD44, CD133, and CXCR4 levels associated with high expression of α2β1-integrin and Oct4 which are reported to be prostate cancer stemness markers. RT-PCR data also revealed high activation of the Sonic Hedgehog signalling pathway in these cells. Additionally, the IGR-CaP1 cells possess a 3D sphere-forming ability and a renewal capacity by maintaining their CSC potential after xenografting in mice. As a result, the hormone-independent IGR-CaP1 cellular clones exhibit the original features of both basal prostate tissue and cancer stemness. Tumorigenic IGR-CaP1 clones constitute invaluable human models for studying prostate cancer progression and drug assessment in vitro as well as in animals specifically for developing new therapeutic approaches targeting prostate cancer stem cells.     

BCL-2 in prostate cancer: a minireview

Prostate cancer progression and the development of androgen-independent prostate cancer have been largely related to a number of genetic abnormality that affect not only the androgen receptor but also crucial molecules involved in the regulation of survival or apoptotic pathways. One of these molecules, the pro-survival protein BCL-2, has been associated with the development of androgen-independent prostate cancer due to its high levels of expression in androgen-independent tumors in advanced stages of the pathology. The upregulation of BCL-2 after androgen ablation in prostate carcinoma cell lines and in a castrated-male rat model further established a connection between BCL-2 expression and prostate cancer progression. This review focuses on the experimental evidence that associates BCL-2 expression with prostate carcinogenesis and cancer progression, and analyzes the evidence that links the phosphatidylinositol 3-kinase (PI 3-kinase)/nuclear factor kappa B (NF-B) survival pathway with the upregulation of BCL-2. The way in which hormone ablation influences this survival pathway and the potential application of novel therapeutic strategies to overcome this anti-apoptotic mechanism is examined.